Taro Pharma (TARO) Misses Q2 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Taro Provides Results for September 30, 2021
October 28, 2021 5:15 PM EDTHAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the quarter and six months ended September 30, 2021.
Quarter ended September 30, 2021 Highlights compared to September 30, 2020
Net sales of $132.0 million decreased $10.9 million. Gross profit of $62.0 million (47.0% of net sales compared to 57.1%) decreased $19.5 million. Research and development (R&D) expenses of $12.5 million decreased $4.1 million. Selling, marketing, general and administrative expenses (SG&A) of $23.7 million were in line with the prior year quarter. Settlements and loss... More